Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Golgi autoantigen, golgin subfamily A, 6-like 2 pseudogene (GOLGA6L2 pseudogene, ENSG00000205976) is identified as a pseudogene in the human genome[1]. Pseudogenes are genomic DNA sequences similar to normal genes but non-functional; they do not encode active proteins due to disabling mutations such as frameshifts, premature stop codons, or promoter disruptions[7]. Though most pseudogenes, including this locus, are not therapeutically actionable, some pseudogenes can regulate parental gene expression through various RNA-based mechanisms, including microRNA decoy activity, antisense regulation, fusion transcripts, or epigenetic modulation (as evidenced for other, but not this specific, pseudogenes)[3][5][7]. There is no evidence that ENSG00000205976 encodes a functional protein, serves as a therapeutic target, interacts with drugs, or is used as a biomarker. Its annotation is correct as a pseudogene, so it is not considered a molecular drug target, and its main relevance is for genomic annotation and potential RNA-level regulation in very specific contexts[1]. Critical Notes: - "GOLGA6L2 pseudogene" is correctly annotated as a pseudogene, not a protein-coding gene, nor is it a classical receptor, enzyme, or transporter[1]. - There is no canonical abbreviation in use for this pseudogene. - It is not associated with any therapeutic drug targeting or established role in disease mechanisms specific to this locus. - As a pseudogene, it is not a druggable target or a clinical biomarker, and no safety concerns are reported. - The entry is not a mistake or misspelling, but as a pseudogene, it is "incorrect" to treat it as a therapeutic or pharmacologically actionable protein target. Summary: This locus is a pseudogene, not a protein target, drug target, or a functional receptor/enzyme/transporter. There are no canonical abbreviations, drugs, mechanisms of action, or biomarkers associated with it. Its main significance lies in genome annotation and potential, but largely unproven, regulatory RNA functions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Golgi autoantigen, golgin subfamily A, 6-like 2 pseudogene.